A Phase 1 Trial of the Oncolytic Virus SVV-001 in Combination With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas or Well-Differentiated High-Grade (Grade 3) Neuroendocrine Tumors

The purpose of this study is to determine:
1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients.
2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients.
3. The highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and tolerability as currently available (standard of care) treatments for patients with neuroendocrine tumors.

开始日期2025-05-19

申办/合作机构

Seneca Therapeutics, Inc.

NCT01017601

/ Terminated临床2期IIT

A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

RATIONALE: A virus called Seneca Valley virus-001 (NTX-010) may be able to kill tumor cells without damaging normal cells. It is not yet known whether NTX-010 is more effective than a placebo in treating small cell lung cancer.
PURPOSE: This randomized phase II trial is studying NTX-010 to see how well it works compared with a placebo when given after chemotherapy in treating patients with extensive-stage small cell lung cancer.

开始日期2010-01-01

申办/合作机构

Alliance Foundation Trials LLC

[+1]

NCT01048892

/ Completed临床1期IIT

A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

RATIONALE: Seneca Valley virus-001 may be able to kill certain kinds of tumor cells without damaging normal cells. Adding low dose cyclophosphamide (in part B of study) may help to kill even more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of Seneca Valley virus-001 in treating young patients with relapsed or refractory neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features.

开始日期2009-09-01

申办/合作机构

The Children's Oncology Group Foundation, Inc.

[+1]

100 项与 NTX-010 相关的临床结果

登录后查看更多信息

100 项与 NTX-010 相关的转化医学

登录后查看更多信息

100 项与 NTX-010 相关的专利（医药）

登录后查看更多信息

项与 NTX-010 相关的文献（医药）

2023-07-06·Journal of translational medicine

Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models.

Article

作者: Suarez, Milagros ; Karthick, Sekar ; Su, Jack M ; Baxter, Patricia A ; Hellenbeck, Paul L ; Qi, Lin ; Xiao, Sophie ; Huang, Yulun ; Abdallah, Aalaa ; Huang, Frank ; Salsman, Vita S ; Ahmed, Nabil M ; Du, Yuchen ; Braun, Frank K ; Zhang, Huiyuan ; Kogiso, Mari ; Li, Xiao-Nan ; Brat, Daniel J ; Patel, Akash J ; Teo, Wan-Yee

BACKGROUND:

Animal models representing different molecular subtypes of glioblastoma multiforme (GBM) is desired for developing new therapies. SVV-001 is an oncolytic virus selectively targeting cancer cells. It's capacity of passing through the blood brain barrier makes is an attractive novel approach for GBM.

MATERIALS AND METHODS:

23 patient tumor samples were implanted into the brains of NOD/SCID mice (1 × 10⁵ cells/mouse). Tumor histology, gene expression (RNAseq), and growth rate of the developed patient-derived orthotopic xenograft (PDOX) models were compared with the originating patient tumors during serial subtransplantations. Anti-tumor activities of SVV-001 were examined in vivo; and therapeutic efficacy validated in vivo via single i.v. injection (1 × 10¹¹ viral particle) with or without fractionated (2 Gy/day x 5 days) radiation followed by analysis of animal survival times, viral infection, and DNA damage.

RESULTS:

PDOX formation was confirmed in 17/23 (73.9%) GBMs while maintaining key histopathological features and diffuse invasion of the patient tumors. Using differentially expressed genes, we subclassified PDOX models into proneural, classic and mesenchymal groups. Animal survival times were inversely correlated with the implanted tumor cells. SVV-001 was active in vitro by killing primary monolayer culture (4/13 models), 3D neurospheres (7/13 models) and glioma stem cells. In 2/2 models, SVV-001 infected PDOX cells in vivo without harming normal brain cells and significantly prolonged survival times in 2/2 models. When combined with radiation, SVV-001 enhanced DNA damages and further prolonged animal survival times.

CONCLUSION:

A panel of 17 clinically relevant and molecularly annotated PDOX modes of GBM is developed, and SVV-001 exhibited strong anti-tumor activities in vitro and in vivo.

2021-12-01·Virology journal3区 · 医学

Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis

3区 · 医学

ArticleOA

作者: Shi, Hongzhe ; Bi, Xingang ; Shou, Jianzhong ; Zhou, Aiping ; Shang, Bingqing ; Xie, Ruiyang

Abstract:

Background:

Oncolytic viruses (OVs) have shown prospects in advanced and metastatic cancer, and many clinical trials have been carried out. To compare OV therapies comprehensively and provide a categorized profile and ranking of efficacy and safety, a network meta-analysis was conducted.

Methods:

A total of 5948 studies were screened and 13 randomized controlled trials with 1939 patients, of whom 1106 patients received OV therapies, comparing four OVs (NTX-010, pexastimogene devacirepvec (Pexa-Vec), talimogene laherparepvec (T-VEC), and pelareorep) were included in a Bayesian network meta-analysis. Eligible studies reported at least one of the following clinical outcome measures: objective response rate (ORR) and grade ≥ 3 adverse events.

Results:

Compared to systemic treatments alone, talimogene laherparepvec (T-VEC) (OR 7.00, 95% CI 1.90–26.00) and T-VEC plus systemic treatment (2.90, 0.80–11.00) showed better objective response rates (ORRs), whereas Pexa-Vec 1 * 109 pfu plus systemic treatment (0.91, 0.26–3.00) and pelareorep plus systemic treatment (1.10, 0.61–2.00) were found to be comparable. The grade ≥ 3 adverse event ranking of the treatments from worst to best was as follows: T-VEC (ranking probability 24%), Pexa-Vec 1 * 109 pfu plus systemic treatment (21%), Pexa-Vec 1 * 109 pfu (17%), T-VEC plus systemic treatment (13%), pelareorep plus systemic treatment (13%), systemic treatments (18%), Pexa-Vec 1 * 108 pfu (12%), and NTX-010 (20%).

Conclusions:

Compared with other oncolytic virus therapies for patients with advanced or metastatic cancer, T-VEC and T-VEC plus systemic treatment appear to provide the best ORR therapy in terms of monotherapy and combination respectively, but should be given with caution to grade ≥ 3 adverse events. Conversely, combining OVs with chemotherapy or target agents was demonstrated not to improve efficacy compared with chemotherapy or target agents alone. Combining OV therapies with immune-checkpoint inhibitors, instead of chemotherapy or target agents, tended to provide better ORRs without causing severe adverse events. This study will guide treatment choice and optimize future trial designs for investigations of advanced or metastatic cancer.

2021-02-01·Veterinary microbiology2区 · 农林科学

Comparison of historical and contemporary isolates of Senecavirus A

2区 · 农林科学

Article

作者: Guo, Baoqing ; Faaberg, Kay S ; Buckley, Alexandra C ; Michael, David D ; Yoon, Kyoung-Jin ; Lager, Kelly M

Senecavirus A (SVA) was discovered as a cell culture contaminant in 2002, and multiple attempts to experimentally reproduce disease were unsuccessful. Field reports of porcine idiopathic vesicular disease (PIVD) cases testing PCR positive for SVA in addition to outbreaks of PIVD in Brazil and the United States in 2015 suggested SVA was a causative agent, which has now been consistently demonstrated experimentally. Ease of experimental reproduction of disease with contemporary strains of SVA raised questions concerning the difficulty of reproducing vesicular disease with historical isolates. The following study was conducted to compare the pathogenicity of SVA between historical and contemporary isolates in growing pigs. Six groups of pigs (n = 8) were intranasally inoculated with the following SVA isolates: SVV001/2002, CAN/2011, HI/2012, IA/2015, NC/2015, SD/2015. All isolates induced vesicular disease in at least half of the inoculated pigs from each group. All pigs replicated virus as demonstrated by serum and/or swab samples positive for SVA by quantitative PCR. Pig sera tested by virus neutralization assay demonstrated cross-neutralizing antibodies against all viruses utilized in the study. Cross-neutralizing antibodies from pigs inoculated with historical isolates were lower than those pigs that were inoculated with contemporary isolates. Phylogenetic analysis revealed two clades with SVV001/2002 being in a separate clade compared to the other five isolates. Although differences in the infection kinetics and sequences of these six isolates were found, clinical presentation of vesicular disease was similar between both historical and contemporary isolates.

项与 NTX-010 相关的新闻（医药）

2025-08-28

·EINPresswire

Seneca Therapeutics Announces the Closing of $3.9 million Series B Extension Round

Funding Provides 2+ Years Runway to Complete Phase I/II Trial of Seneca Vally Virus (SVV-001) Currently Underway in High-Grade Neuroendocrine Neoplasms PHILADELPHIA, PA, UNITED STATES, August 28, 2025 / EINPresswire.com / -- Seneca Therapeutics, Inc., announced today the closing of its $3.9 million Series B Extension Round. “We are excited about this raise, which provides the Company sufficient cash through 2027 and allows us to advance our goal of developing revolutionary treatments for solid tumors,” said Cuong Do, Executive Chairman at Seneca Therapeutics. “This will provide funding to complete our currently enrolling Phase I/II trial of SVV-001 in high-grade neuroendocrine neoplasms.” The currently underway Phase I/II trial of SVV-001 (NCT06889493) will assess the safety and preliminary efficacy of SVV-001 in combination with the checkpoint inhibitors nivolumab and ipilimumab for the treatment of high-grade neuroendocrine neoplasms. The trial will enroll 21-30 patients in three single-ascending dose cohorts and two multiple-ascending dose cohorts. A 15-patient expansion cohort is also planned. The trial is anticipated to take 12-18 months to complete. “Patients with high-grade neuroendocrine neoplasm don’t respond well to checkpoint inhibitor immunotherapies as these cancers are usually devoid of T-cells within the tumor environment – referred to as cold tumors – that are necessary for effective treatment,” said Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics. “In pre-clinical studies, SVV-001 has shown the ability to draw in T-cells into the tumors thus making the cold tumors ‘hot’ and increase the response to checkpoint inhibitors and stimulating an anti-tumor immune response. We believe that by combining SVV-001 with dual checkpoint blockade of nivolumab and ipilimumab, we will enhance anti-tumor immunity and observe higher response rates.” The receptor of SVV-001, tumor endothelial marker 8 (TEM8), is a protein that is expressed by many solid tumors, and studies have shown that the high expression of TEM8 lowers survival rates across a number of solid tumor indications, including small cell lung cancer (a high-grade neuroendocrine neoplasm), bladder cancer, cervical cancer, breast cancer, and gastric cancer. High-grade neuroendocrine tumors and carcinomas are difficult-to-treat, and the objective response rates to treatment typically range from 5% to 20%. SVV-001 selectively binds to TEM8 expressed by tumor cells, infects and kills these cells, and elicits a systemic anti-tumor immune response. A wealth of pre-clinical data, epidemiology studies, and three prior clinical trials have shown that SVV-001 infection is highly specific to solid cancer cells. SVV-001 is being developed as a TEM8 therapeutic, with the aim of enhancing response rate and survival. In preclinical studies, SVV-001 administered in conjunction with nivolumab and ipilimumab eradicated tumors, induced a systemic anti-tumor immune response, and dramatically extended survival. This Phase I/II trial aims to replicate the preclinical data in patients with high-grade neuroendocrine tumors and carcinomas. About Seneca Therapeutics Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV-001 and its binding specificity to TEM8, an important emerging cancer marker expressed in the majority of solid tumors. A SVV-001 Phase I/II trial recently started to further the clinical development of SVV-001. We anticipate initial data read out from this clinical trial in the second half of 2026 or first half of 2027. The Company has also developed an SVV-001 Companion Diagnostic that can identify patients whose tumor expresses TEM8 and may be susceptible to SVV-001 treatment. The Company is in the process of validating the diagnostic to be used in future clinical trials to identify patients that would benefit from SVV-001. Learn more at NULL www.senecatherapeutics.com . Forward-Looking Statements This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason. Contact: Cuong Do Paul Hallenbeck, PhD Executive Chairman President and CSO cdo@senecatherapeutics.com paulhallenbeck@senecatherapeutics.com Franco et al. Front. Mol. Biosci. 11:1520223 Ilie et al. Neuroendocrinology (2023) 113 (2): 262–278 Al-Toubah et al. doi: 10.1016/j.esmoop.2024.102386. Bai et al. Cancer Biol Med. 2022 Oct 18;19(12):1649–1661 James Hussey Seneca Therapeutics +1 847-507-0033 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床研究免疫疗法

2025-05-27

·EINPresswire

Seneca Therapeutics Announces the Dosing of the First Patient in the SVV-001 Phase I/II Trial

Trial to Demonstrate Safety and Preliminary Efficacy with Poorly Differentiated Neuroendocrine Carcinomas or High-Grade (Grade 3) Neuroendocrine Tumors PHILADELPHIA, PA, UNITED STATES, May 27, 2025 / EINPresswire.com / -- Seneca Therapeutics announced today the dosing of the first patient in the SVV-001 Phase I/II clinical trial in high grade neuroendocrine neoplasms. The Phase I/II trial will assess the safety and preliminary efficacy of Seneca Valley Virus (SVV-001) in combination with the checkpoint inhibitors nivolumab and ipilimumab in the treatment of high-grade neuroendocrine neoplasms. The trial will be conducted at one of the leading NCI designated cancer centers in the United States. It will enroll 21-30 patients in three single ascending dose (SAD) cohorts and three multiple ascending dose (MAD) cohorts. The trial is anticipated to take 12-18 months to complete. “We are very excited about the initiation of this trial,” said Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics. “Unfortunately, this patient population has cancers that don’t respond well with checkpoint inhibitors as they are usually devoid of T cells within the tumor (referred to as cold tumors) that are necessary for effective therapy with checkpoint inhibitors. SVV-001 has shown the ability to turn these tumors ‘hot’ and increase the response to standard of care in preclinical studies. We believe that this trial’s combination of SVV-001 with nivolumab and ipilimumab should demonstrate higher response rates. The receptor of SVV-001, tumor endothelial marker 8 (TEM8), is a tumor-specific antigen that is expressed by many solid tumors, and studies have shown that high expression of TEM8 lowers survival across a number of solid tumor indications, including small cell lung cancer (a high-grade neuroendocrine neoplasm), bladder cancer, cervical cancer, breast cancer, and gastric cancer. High-grade neuroendocrine tumors and carcinomas are difficult to treat, and the objective response rates to treatment typically range from 5% to 20%. SVV-001 selectively binds to TEM8 expressed by tumor cells, infects and kills these cells, and elicits a systemic anti-tumor immune response. A wealth of pre-clinical data, epidemiology studies, and all three prior clinical trials have shown that SVV-001 does not infect any normal human cells. SVV-001 is being developed as a TEM8 therapeutic with the aim of enhancing response rate and survival. In preclinical studies, SVV-001 administered in conjunction with nivolumab and ipilimumab eradicated the tumors, induced a systemic anti-tumor immune response, and dramatically extended survival. This Phase I/II trial hopes to replicate the preclinical data in patients with high-grade neuroendocrine tumors and carcinomas. About Seneca Therapeutics Seneca Therapeutics is a clinical stage company developing SVV-001 for various tumor types. SVV-001 has been shown to selectively bind TEM8, and specifically infect and kill these cells. TEM8 is an important emerging cancer marker expressed by the majority of solid tumors. The presence of TEM8 has been shown to render tumors resistant to treatments and dramatically shorten survival. Three prior clinical trials observed no toxicities when patients were given a single dose of SVV-001 delivered via systemic intravenous administration. The company has initiated a Phase I/II to evaluate the safety and efficacy of multiple doses of SVV-001 in combination with standard of care to treat patients with high-grade neuroendocrine tumors and carcinomas. Additional indications are anticipated Forward-Looking Statements This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason. Contact: Walter Greenblatt Walter Greenblatt & Associates LLC walter@wgreenblatt.com www.senecatherapeutics.com James Hussey Seneca Therapeutics +1 847-507-0033 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床研究免疫疗法

2023-12-11

·Business Wire

Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to Present at Oncolytic Virotherapy Summit 2023 on December 13

PHILADELPHIA--( BUSINESS WIRE )--Seneca Therapeutics, Inc. (STI), announced today that Dr. Paul Hallenbeck will present a talk at the 8th Oncolytic Virotherapy Summit 2023 entitled “ Assessing the Benefits and Challenges of Intravenous Delivery of Oncolytic Viruses” . In his talk, Dr. Hallenbeck will discuss the challenges inherent in doing multiple (IV) intravenous administrations of oncolytic viruses, where the field is meeting these challenges, and present data on the development of multiple IV technology for STI’s oncolytic virus SVV-001, a clinical stage oncology product. “There are several important hurdles to be overcome to develop the capability of performing multiple intravenous delivery of an oncolytic virus,” said Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics. “These include cost of goods, high cancer target selectivity, elimination and/or avoidance of existing neutralizing antibodies and obtaining significant replication at the tumor site. SVV-001 has the profile to potentially meet all these multiple challenges.” About Seneca Therapeutics Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 that create additional anti-tumor effects. Forward-Looking Statements This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason. www.senecatherapeutics.com

临床研究

100 项与 NTX-010 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB06129

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经内分泌肿瘤	临床2期	美国	Seneca Therapeutics, Inc.	2022-10-03
小细胞肺癌	临床2期	-	Novartis Pharma AG	-
APUD瘤	临床1期	美国	Seneca Therapeutics, Inc.	2025-05-19
大细胞神经内分泌癌	临床1期	美国	Seneca Therapeutics, Inc.	2025-05-19
晚期恶性实体瘤	临床1期	美国	Neotropix, Inc.	2006-04-01
类癌	临床1期	美国	Neotropix, Inc.	2006-04-01
肿瘤	临床前	-	Seneca Therapeutics, Inc.	2022-04-11
实体瘤	临床前	美国	Seneca Therapeutics, Inc.	2021-04-27
弥漫内生性脑桥神经胶质瘤	临床前	美国	Baylor College of Medicine	2017-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06889493 (ESMO2025)	临床1期	神经内分泌肿瘤 \| 神经内分泌癌 Tumor endothelial marker 8 (TEM8)	36	SVV-001+nivolumab+ipilimumab	範鬱鹹衊襯襯衊鏇廠鑰(窪觸遞廠範構範齋選網) = 範鏇窪醖夢範獵窪願願範憲餘淵壓觸廠齋繭築 (築繭獵醖顧範獵醖遞繭 )	积极	2025-10-17
NCT01017601 (N0923, Pubmed) 人工标引	临床2期	广泛期小细胞肺癌	50	NTX-010	鏇糧鹽簾遞艱鹽鹹蓋齋(窪壓選餘願鏇醖範糧鹽) = 憲夢範網艱窪鏇蓋齋網範淵衊蓋淵繭構顧廠鏇 (鹹鑰艱憲遞艱獵艱鹹醖, 1.4 ~ 3.1) 更多	不佳	2020-01-01
				Placebo	鏇糧鹽簾遞艱鹽鹹蓋齋(窪壓選餘願鏇醖範糧鹽) = 遞鏇顧窪憲淵鹹糧顧糧範淵衊蓋淵繭構顧廠鏇 (鹹鑰艱憲遞艱獵艱鹹醖, 1.4 ~ 4.3) 更多
NCT01017601 (N0923 \| Alliance (NCCTG) N0923, CTgov)	临床2期	广泛期小细胞肺癌	59	Seneca Valley virus-001 (NTX-010) (Arm I (NTX-010))	積膚淵膚鑰選醖醖積鑰(襯糧襯夢鹹蓋夢襯鑰蓋) = 憲鏇窪糧壓選鹽淵鹽鏇鏇範鑰鹹顧窪醖構顧顧 (積齋醖鹽觸餘鬱襯鏇遞, 觸衊艱醖鏇鏇網鹽鹹夢 ~ 構積艱製襯簾糧繭遞顧) 更多	-	2017-05-08
				Placebo (Arm II (Placebo))	積膚淵膚鑰選醖醖積鑰(襯糧襯夢鹹蓋夢襯鑰蓋) = 鏇選膚鹹選築壓積網網鏇範鑰鹹顧窪醖構顧顧 (積齋醖鹽觸餘鬱襯鏇遞, 夢簾壓憲範憲醖廠艱鑰 ~ 憲淵鬱簾餘選簾齋艱衊) 更多
N-0923 (WCLC2013)	N/A	广泛期小细胞肺癌	-	NTX-010	餘醖製醖鹽鹽繭繭蓋願(簾構網窪觸繭選選淵衊) = 範願鹽遞積範衊鹽鹹醖繭簾製膚窪糧願餘鏇憲 (艱構構醖憲製鬱醖鏇網, 1.3 ~ 3.1)	-	2013-10-29
				Placebo	餘醖製醖鹽鹽繭繭蓋願(簾構網窪觸繭選選淵衊) = 艱窪選簾襯選選齋範築繭簾製膚窪糧願餘鏇憲 (艱構構醖憲製鬱醖鏇網, 1.4 ~ 4.3)
NCT01017601 (Alliance (NCCTG) N0923, ASCO2013)	临床2期	广泛期小细胞肺癌	59	NTX-010	壓遞壓獵築鏇鏇鹹遞繭(網範醖顧衊獵選鏇齋衊) = 鏇蓋鏇襯築鬱廠網鹽壓艱壓鹹壓願壓艱觸選構 (艱醖蓋鹹製積簾壓鹹壓, 1.3 ~ 3.1)	不佳	2013-05-20
				Placebo	壓遞壓獵築鏇鏇鹹遞繭(網範醖顧衊獵選鏇齋衊) = 憲艱積鹹鹹廠衊壓遞顧艱壓鹹壓願壓艱觸選構 (艱醖蓋鹹製積簾壓鹹壓, 1.4 ~ 4.3)
ASCO2009	临床1期	神经内分泌肿瘤	30	NTX-010	網廠觸淵網淵夢觸遞觸(鹹網網鏇鹽淵淵築齋餘) = 壓選遞夢蓋鑰壓膚觸壓壓獵網鏇餘醖窪鏇壓獵 (窪觸築觸網衊蓋製憲壓 ) 更多	-	2009-05-20
Phase I Study of Seneca Valley Virus (SVV-001) (ASGCT2009)	临床1期	神经内分泌肿瘤	30	SVV-001 10^7 vp/kg	衊繭簾遞鏇蓋鏇夢膚觸(艱醖齋憲範築糧糧齋願) = 獵願襯淵糧顧艱鹹憲鬱夢齋觸醖繭蓋餘鏇憲鑰 (範簾觸廠憲醖遞壓壓觸 ) 更多	积极	2009-05-01
				SVV-001 10^11 vp/kg	衊繭簾遞鏇蓋鏇夢膚觸(艱醖齋憲範築糧糧齋願) = 膚醖膚鬱憲築範膚簾築夢齋觸醖繭蓋餘鏇憲鑰 (範簾觸廠憲醖遞壓壓觸 ) 更多